Syneos Health (SYNH) announced a strategic multi-year agreement with Microsoft (MSFT). Utilizing Microsoft Azure services, Syneos Health has developed an advanced analytics platform that enables agile deployment of machine learning supporting the analysis, design and execution of clinical trials and commercial programs worldwide. The multi-year agreement includes collaboration with Microsoft Research and leverages developments from OpenAI. Through this collaboration, Syneos Health will deliver technology and data solutions with Microsoft that accelerate clinical development and elevate commercial performance for biopharma customers.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SYNH:
- Syneos Health Collaborates with Microsoft to Accelerate AI Across the Clinical to Commercial Continuum
- Syneos Health price target raised to $45 from $30 at Barclays
- Syneos Health launches Decentralized Clinical Trial Site Network
- Syneos Health Unveils New Decentralized Clinical Trial Site Network to Drive DCT Adoption
- Baird sees more value in Syneos than market, but says buyer would ‘need resolve’
